BBIO vs. HUT

Last updated Aug 1, 2026

BBIO (BridgeBio Pharma, Inc.) and HUT (Hut 8 Corp.) are both stocks. BBIO operates in Biotechnology (Healthcare), while HUT operates in Capital Markets (Financial Services). Over the past 5 years, BBIO returned 8.42%/yr vs 35.40%/yr for HUT. Their 0.27 correlation means their historical movements had little consistent relationship.

Performance

BBIO vs. HUT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in BridgeBio Pharma, Inc. (BBIO) and Hut 8 Corp. (HUT). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, BBIO achieves a 4.71% return, which is significantly lower than HUT's 134.28% return.

BBIO

• 1D: -2.50%
• 1M: 7.47%
• 6M: 3.65%
• YTD: 4.71%
• 1Y: 69.43%
• 3Y*: 32.71%
• 5Y*: 8.42%
• 10Y*: —
• ALL TIME*: 14.52%

HUT

• 1D: -0.59%
• 1M: 1.74%
• 6M: 92.78%
• YTD: 134.28%
• 1Y: 406.97%
• 3Y*: 85.18%
• 5Y*: 35.40%
• 10Y*: —
• ALL TIME*: 23.81%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison

Position	Avg. Volume Value (2W)	Avg. Volume Value (1M)	Avg. Volume Value (3M)
BBIO BridgeBio Pharma, Inc.	$163.36M	$283.28M	$252.33M
HUT Hut 8 Corp.	$525.36M	$446.23M	$513.46M

BBIO vs. HUT - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019
BBIO BridgeBio Pharma, Inc.	4.71%	178.75%	-32.03%	429.79%	-54.32%	-76.54%	102.88%	14.51%
HUT Hut 8 Corp.	134.28%	124.21%	53.60%	213.88%	-89.17%	185.45%	250.63%	-64.83%

Correlation

The correlation between BBIO and HUT is 0.18, which is low. Their historical price movements had little consistent relationship.

	Correlation
Correlation (1Y) Focuses on recent behavior, but can change the most.	0.18
Correlation (3Y) Balances recent behavior with more history.	0.26
Correlation (5Y) Shows whether the relationship held over a longer period.	0.32
Correlation (All Time) Calculated using the full available price history since Jun 27, 2019	0.27

The correlation between BBIO and HUT shifts across timeframes, from 0.18 (1 year) to 0.32 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap BBIO : $15.69B HUT : $12.12B
EPS BBIO : -$3.74 HUT : -$2.77
Total Revenue (TTM) BBIO : $566.04M HUT : -$40.96M
Gross Profit (TTM) BBIO : $538.20M HUT : -$132.19M
EBITDA (TTM) BBIO : -$602.24M HUT : -$306.16M

Return for Risk

BBIO vs. HUT — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

BBIO

BBIO Risk / Return Rank: 85
BBIO Sharpe Ratio Rank: 84
BBIO Sortino Ratio Rank: 82
BBIO Omega Ratio Rank: 83
BBIO Calmar Ratio Rank: 89
BBIO Martin Ratio Rank: 87

HUT

HUT Risk / Return Rank: 97
HUT Sharpe Ratio Rank: 99
HUT Sortino Ratio Rank: 95
HUT Omega Ratio Rank: 93
HUT Calmar Ratio Rank: 99
HUT Martin Ratio Rank: 98

The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

BBIO vs. HUT - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for BridgeBio Pharma, Inc. (BBIO) and Hut 8 Corp. (HUT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	BBIO	HUT	Difference
Sharpe ratio: Return per unit of total volatility	1.44	3.81	-2.37
Sortino ratio: Return per unit of downside risk	2.16	3.35	-1.19
Omega ratio: Gain probability vs. loss probability	1.28	1.41	-0.12
Calmar ratio: Return relative to maximum drawdown	3.45	10.62	-7.18
Martin ratio: Return relative to average drawdown	7.74	26.07	-18.33

BBIO vs. HUT - Sharpe Ratio Comparison

The current BBIO Sharpe Ratio is 1.44, which is lower than the HUT Sharpe Ratio of 3.81. The chart below compares the historical Sharpe Ratios of BBIO and HUT, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

BBIO vs. HUT - Drawdown Comparison

The maximum BBIO drawdown since its inception was -92.80%, roughly equal to the maximum HUT drawdown of -95.04%. Use the drawdown chart below to compare losses from any high point for BBIO and HUT.

Drawdown Indicators

	BBIO	HUT	Difference
Max Drawdown Largest peak-to-trough decline	-92.80%	-95.04%	+2.24%
Max Drawdown (1Y) Largest decline over 1 year	-20.25%	-38.62%	+18.37%
Max Drawdown (3Y) Largest decline over 3 years	-49.08%	-65.08%	+16.00%
Max Drawdown (5Y) Largest decline over 5 years	-90.72%	-95.04%	+4.32%
Current Drawdown Current decline from peak	-11.18%	-19.09%	+7.91%
Average Drawdown Average peak-to-trough decline	-45.08%	-62.83%	+17.75%
Ulcer Index Depth and duration of drawdowns from previous peaks	9.00%	15.71%	-6.71%

Volatility

BBIO vs. HUT - Volatility Comparison

The current volatility for BridgeBio Pharma, Inc. (BBIO) is 17.23%, while Hut 8 Corp. (HUT) has a volatility of 37.29%. This indicates that BBIO experiences smaller price fluctuations and is considered to be less risky than HUT based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	BBIO	HUT	Difference
Volatility (1M) Calculated over the trailing 1-month period	17.23%	37.29%	-20.06%
Volatility (6M) Calculated over the trailing 6-month period	37.06%	76.96%	-39.90%
Volatility (1Y) Calculated over the trailing 1-year period	48.65%	107.84%	-59.19%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	86.05%	105.81%	-19.76%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	83.29%	114.67%	-31.38%

Dividends

BBIO vs. HUT - Dividend Comparison

Neither BBIO nor HUT has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both BBIO and HUT in my portfolio?

BBIO and HUT have a correlation of 0.18, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, BBIO or HUT?

HUT has higher volatility (37.29%) compared to BBIO (17.23%). In terms of maximum drawdown, BBIO dropped -92.80% vs HUT's -95.04%.

Which has better risk-adjusted returns?

HUT currently has the higher Sharpe Ratio (3.81 vs 1.44), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.